It works by mimicking a hormone called glucagon-like peptide-1, or GLP-1, which stimulates the body’s production of insulin.

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with ...

Image credit: James Manning – PA Images/Getty Images. Glucagon-like peptide-1 receptor agonists (GLP-1) drugs are a class of medications used to manage type 2 diabetes and treat obesity.

Glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food. Both diabetes and obesity ...

"This finding suggests that it may be beneficial to reassess the preoperative withholding guidelines for GLP-1 RAs." HealthDay News — Preoperative glucagon-like peptide-1 receptor agonist (GLP-1 ...

A Central Illinois cardiologist breaks down the potential benefits of GLP-1 medications on heart health. It was one of the ...

Back to Healio Sodium-glucose cotransporter 2, or SGLT2, inhibitors may be more cardioprotective for older adults, whereas glucagon-like peptide-1 receptor agonists may confer greater HbA1c ...